Yes, GHK/Epi/MOTS integrates well with comprehensive longevity protocols including other peptides, hormone optimization, NAD+ therapy, senolytics, cosmetic procedures, exercise programs, and dietary interventions
The recommended schedule from clinical trials is: Weeks 1-4: 2.5 mg once weekly Weeks 5-8: 5 mg once weekly Weeks 9-12: 7.5 mg once weekly Weeks 13-16: 10 mg once weekly Weeks 17-20: 12.5 mg once weekly Week 21+: 15 mg once weekly (maximum dose) Not everyone follows this exact schedule
Rats were pretreated with icv scopolamine (70 nmol in 2 aCSF) 20 min prior to training followed by the icv infusion of dihexa (0.1 or 1 nmol in 2 aCSF) 5 min prior to daily training
Research applications: cytoprotection, angiogenesis and tissue-repair models
In one study, the potentially significant role of glutamine in this phenomenon was observed [49]
GHK-Cu and BPC-157 are not specifically named on the current Prohibited List